, Volume 162, Issue 10, pp 723-724
Date: 07 Aug 2003

Paroxetine withdrawal in a neonate with historical and laboratory confirmation

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
This is an excerpt from the content

We describe a term neonate born to a mother who stopped paroxetine intake 48 h prior to birth, who had features suggestive of paroxetine withdrawal and supported by paroxetine not being detected in plasma and cerebrospinal fluid showing no change in serotonin metabolites.

The use of serotonin re-uptake inhibitors (SSRIs) during the pregnancy is now common [1,2]. A constellation of clinical features have been recognised in babies of mothers on SSRIs in their third trimester. However, there is ongoing discussion as to whether the symptoms are due to withdrawal [3, 4,13] or an hyperserotinergic state [6, 9,12]. Here we describe a term neonate with symptoms that were consistent with previous cases of neonatal SSRI (paroxetine) withdrawal syndrome. In addition, plasma concentrations of paroxetine and cerebrospinal fluid (CSF) concentrations of 5-hydroxyindoleacetic acid (5-HIAA) were measured.

A full term neonate was admitted to the neonatal intensive care unit immediately after birth because ...